Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

Rhea-AI Summary

Sonora Quest Laboratories (NYSE:DGX) named Jennifer Erickson as Chief Executive Officer‑Elect, succeeding longtime CEO David Dexter, who will retire effective March 31, 2026. Dexter will work with Erickson starting Feb. 2, 2026 to complete a planned transition. Dexter led the company for more than 26 years, overseeing growth to a market‑share leadership position in Arizona and operations performing more than 100 million diagnostic tests per year. Erickson brings over 20 years of health‑care leadership and previously served as Sonora Quest CFO (1999–2004).

Positive

• Planned transition window from Feb. 2 to Mar. 31, 2026
• Jennifer Erickson brings >20 years of health‑care leadership experience
• Internal successor with prior Sonora Quest CFO role (1999–2004)
• Continuity emphasized: CEO mentor relationship spans 26 years

Negative

• Departure of CEO David Dexter after >26 years of leadership
• Potential short‑term execution risk during leadership handover through March 31, 2026

News Market Reaction

+1.87%

1 alert

+1.87% News Effect

On the day this news was published, DGX gained 1.87%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Leadership tenure: more than 26 years Annual test volume: more than 100 million diagnostic tests per year Transition start date: Feb. 2 +5 more

8 metrics

Leadership tenure more than 26 years David Dexter’s service leading Sonora Quest and LSA

Annual test volume more than 100 million diagnostic tests per year Sonora Quest testing volume under Dexter’s leadership

Transition start date Feb. 2 Date Dexter begins working closely with Erickson on transition

Retirement date March 31 Date Dexter retires as CEO of Sonora Quest and LSA

Direct-access launch 2015 Launch year for My Lab ReQuest direct-access testing platform

COVID-19 capacity initiative 2020 Year Operation Catapult expanded COVID-19 diagnostic testing

Erickson experience more than 20 years Experience leading high-performance health care and consumer services companies

Former CFO tenure 1999 to 2004 Erickson’s prior role as Sonora Quest Chief Financial Officer

Market Reality Check

Price: $205.35 Vol: Volume 1,494,677 is 1.65x...

high vol

$205.35 Last Close

Volume Volume 1,494,677 is 1.65x the 20-day average of 903,823, indicating elevated interest before this headline. high

Technical Shares at $186.77 are above the 200-day MA of $177.75 and about 5.46% below the $197.55 52-week high.

Peers on Argus

DGX gained 3.78% with strong volume while key peers were mixed: LH +2.89%, NTRA ...

DGX gained 3.78% with strong volume while key peers were mixed: LH +2.89%, NTRA +1.48%, MTD +0.38%, WAT -0.21%, PKI 0%. Moves do not show a clear sector-wide pattern.

Historical Context

5 past events · Latest: Jan 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Earnings timing	Neutral	-0.2%	Announced date and call details for Q4 and full-year 2025 results.
Jan 06	Clinical data update	Positive	+4.0%	Haystack MRD® data to be presented at 2026 ASCO GI symposium.
Jan 05	Joint venture deal	Positive	-0.2%	Completed Diagnostic Lab of Michigan JV with Corewell Health.
Dec 19	Conference appearance	Neutral	-0.1%	Planned presentation at the 44th J.P. Morgan Healthcare Conference.
Dec 09	Clinical collaboration	Positive	-1.2%	Haystack MRD collaboration for Phase II MRD-PORT lung cancer trial.

Pattern Detected

Recent DGX news shows mixed reactions: positive scientific and partnership updates sometimes align with gains, but there are also instances where constructive news coincided with modest declines.

Recent Company History

Over the past months, Quest Diagnostics has highlighted several strategic and scientific developments. A Michigan joint venture expanded lab access, and multiple Haystack MRD® updates underscored its oncology focus, including ASCO GI data and a lung cancer trial collaboration noted in 2025. Investor communications have included J.P. Morgan conference materials and upcoming Q4/FY 2025 earnings timing. Against this backdrop, today’s leadership-related announcement at a key affiliate fits into a narrative of ongoing network and capability expansion.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-06-20

Quest Diagnostics has an effective S-3ASR automatic shelf registration filed on 2025-06-20, allowing it to issue various debt securities on a delayed or continuous basis under Rules 415 and 462(e). Specific terms and sizing would be detailed only in future prospectus supplements. The filing emphasizes risks including competition, regulatory compliance, acquisition integration, cybersecurity, and macroeconomic factors.

Market Pulse Summary

This announcement highlights a leadership transition at Sonora Quest and Laboratory Sciences of Ariz...

Analysis

This announcement highlights a leadership transition at Sonora Quest and Laboratory Sciences of Arizona, long-standing partners in the diagnostic testing ecosystem, with David Dexter retiring after more than 26 years and Jennifer Erickson named CEO-elect. The article underscores operational scale of more than 100 million diagnostic tests per year and past innovations like direct-access testing and COVID-19 capacity initiatives. Investors may watch how governance continuity, partnerships, and capital structure tools such as the company’s effective S-3ASR debt shelf support Quest’s broader strategic objectives.

Key Terms

clinical laboratory testing, diagnostic tests, direct-access testing, COVID-19 diagnostic testing

4 terms

clinical laboratory testing medical

"serving as the market share leader in clinical laboratory testing in Arizona"

Clinical laboratory testing is the process of analyzing blood, tissue, or other patient samples to measure chemicals, cells, proteins, or genetic markers that help diagnose disease, monitor health, or guide treatment. For investors, these tests are a core part of healthcare revenue and innovation — like a dashboard for a car, they translate raw biological signals into actionable information that drives demand for labs, instruments, reagents, and related services.

diagnostic tests medical

"performing more than 100 million diagnostic tests per year"

Diagnostic tests are assessments used to evaluate the health or condition of a company or market to identify potential issues or opportunities. They help investors understand underlying strengths or risks, much like a medical check-up reveals health status before symptoms appear. By providing insights into financial stability or vulnerabilities, diagnostic tests support more informed investment decisions.

direct-access testing medical

"development of its direct-access testing platform, My Lab ReQuest™, in 2015"

Direct-access testing is the sale of medical or laboratory tests straight to consumers without requiring a doctor’s order, like buying a home pregnancy test or a mail-in blood panel. It matters to investors because it changes how healthcare services are sold and scaled—companies can reach customers faster and generate recurring revenue, but they also face regulatory scrutiny, quality expectations, and competition that can affect growth and profitability.

COVID-19 diagnostic testing medical

"Operation Catapult to expand Sonora Quest's COVID-19 diagnostic testing capacity in 2020"

COVID-19 diagnostic testing means medical tests that check whether a person currently has the virus that causes COVID-19 or has mounted an immune response after past infection. Think of them as sensors that reveal where the virus is and how widespread it is. Investors care because test availability, accuracy and regulatory approval drive sales, affect healthcare spending and influence economic activity and market confidence much like early warning systems guide business decisions.

AI-generated analysis. Not financial advice.

Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service

PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership.

Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the market share leader in clinical laboratory testing in Arizona and performing more than 100 million diagnostic tests per year.

Starting on Feb. 2, Dexter will work closely with Erickson to ensure a smooth transition over the coming months. Dexter will be retiring as of March 31.

"As I've reflected on my years as CEO, I have a blend of emotions — gratitude, pride, and nostalgia," said Dexter. "My fondest memories aren't of milestones reached or metrics made, but of the people with whom I've worked, the resilience during challenges and tough times, and the creativity and innovation that's been brought to every opportunity."

Dexter has led Sonora Quest and LSA through many major milestones, including the development of its direct-access testing platform, My Lab ReQuest™, in 2015, and the launch of Operation Catapult to expand Sonora Quest's COVID-19 diagnostic testing capacity in 2020. He also supported many ongoing collaborations with community partners, such as the American Cancer Society, Aunt Rita's Foundation, and CommunityCares, helping broaden the reach of diagnostic testing for patients statewide. Together, these efforts strengthened access, innovation, and resilience across Arizona's diagnostic landscape.

Erickson will continue Dexter's legacy of growth and innovation. As an executive with a proven track-record in driving performance, culture and profitability, Erickson will continue to focus on advancing patient-centered diagnostics, strengthening partnerships and fostering a culture of collaboration and accountability.

Dexter noted, "I personally have mentored Jennifer for 26 years, and have had the privilege of working alongside her during that time. I know that she is an excellent fit for the role and am very confident that she will carry on the spirit of a fearless leader."

Erickson brings more than 20 years of experience leading high-performance health care and consumer services companies; most recently as Chief Financial Officer and Chief Operating Officer of Clin-Path Associates/Pathology Specialists of Arizona. She also has deep knowledge of the Sonora Quest, LSA and Banner Health governance models, having previously served as Sonora Quest Chief Financial Officer from 1999 to 2004.

"Returning to lead the company that gave me such a strong foundation in health care leadership, now in the role once held by my mentor, is both an honor and great responsibility," said Erickson. "This is a full-circle moment that underscores the lasting impact of strong leadership and intentional mentorship. I look forward to building on a legacy defined by forward thinking, meaningful relationships, and care for the people we serve."

For more information about Sonora Quest, and LSA, visit www.SonoraQuest.com.

About Sonora Quest Laboratories

Sonora Quest Laboratories, a subsidiary of Laboratory Sciences of Arizona, is an Arizona-based joint venture between Banner Health and Quest Diagnostics (NYSE: DGX) that makes up one of the nation's largest integrated laboratory systems. We are the trusted leader in diagnostic and information services with approximately 3,900 employees performing more than 100 million diagnostic tests per year. Our comprehensive test menu encompasses routine, molecular, prescription drug monitoring, genetic/genomic, women's health, and pathology testing services. Sonora Quest is accredited by the College of American Pathologists, the gold standard in laboratory accreditation, which helps ensure the highest standard of care for laboratory operations. To schedule an appointment, find one of our 70+ patient service centers across Arizona, or learn more about ordering tests without a provider's order through My Lab ReQuest™, visit us at SonoraQuest.com.

MEDIA CONTACT
LAVIDGE
SQL@lavidge.com
480.998.2600 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sonora-quest-and-laboratory-sciences-of-arizona-announce-jennifer-erickson-as-ceo-elect-302662219.html

SOURCE Sonora Quest Laboratories

FAQ

Who is the new CEO‑elect of Sonora Quest (DGX) and when does she take over?

Jennifer Erickson was named CEO‑elect; she will complete transition with current CEO and the retirement is effective March 31, 2026.

When does the Sonora Quest (DGX) leadership transition begin?

The handover begins Feb. 2, 2026, with a planned transition through March 31, 2026.

What experience does Sonora Quest CEO‑elect Jennifer Erickson have for DGX investors?

Erickson has >20 years leading health‑care and consumer services firms and served as Sonora Quest CFO from 1999 to 2004.

Why is David Dexter retiring from Sonora Quest (DGX) notable for investors?

Dexter led Sonora Quest for more than 26 years and oversaw growth to >100 million annual diagnostic tests, so his retirement is a material leadership change.

Will the Sonora Quest (DGX) CEO change affect daily operations immediately?

The company announced a planned, phased transition to maintain continuity; no immediate operational changes were disclosed.

How does Jennifer Erickson’s appointment affect Sonora Quest (DGX) strategic direction?

The announcement says Erickson will continue focus on patient‑centered diagnostics, partnerships, and culture; no new strategic shifts or financial guidance were disclosed.